Concord Drugs Ltd
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- ₹33.6
- Today's High:
- ₹36.75
- Open Price:
- ₹36.5
- 52W Low:
- ₹24.8
- 52W High:
- ₹41.65
- Prev. Close:
- ₹36.45
- Volume:
- 26195
Company Statistics
- Market Cap.:
- ₹344.33 million
- Book Value:
- Revenue TTM:
- ₹0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- ₹88.82 million
- Profit Margin:
- 0%
- Return on Assets TTM:
- 0%
- Return on Equity TTM:
- 0%
Company Profile
Concord Drugs Ltd had its IPO on under the ticker symbol CONCORD.
The company operates in the sector and industry. Concord Drugs Ltd has a staff strength of 0 employees.
Stock update
Shares of Concord Drugs Ltd opened at ₹36.5 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of ₹33.6 - ₹36.75, and closed at ₹35.18.
This is a -3.48% slip from the previous day's closing price.
A total volume of 26,195 shares were traded at the close of the day’s session.
In the last one week, shares of Concord Drugs Ltd have slipped by -3.4%.
Concord Drugs Ltd's Key Ratios
Concord Drugs Ltd has a market cap of ₹344.33 million, indicating a price to book ratio of 0.9927 and a price to sales ratio of 0.5526.
In the last 12-months Concord Drugs Ltd’s revenue was ₹0 with a gross profit of ₹88.82 million and an EBITDA of ₹0. The EBITDA ratio measures Concord Drugs Ltd's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Concord Drugs Ltd’s operating margin was 0% while its return on assets stood at 0% with a return of equity of 0%.
In Q1, Concord Drugs Ltd’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Concord Drugs Ltd’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 95.3511
- PEG
Its diluted EPS in the last 12-months stands at ₹0 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Concord Drugs Ltd’s profitability.
Concord Drugs Ltd stock is trading at a EV to sales ratio of 0.8073 and a EV to EBITDA ratio of 11.7089. Its price to sales ratio in the trailing 12-months stood at 0.5526.
Concord Drugs Ltd stock pays annual dividends of ₹ per share, indicating a yield of None and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- ₹582.31 million
- Total Liabilities
- ₹216.15 million
- Operating Cash Flow
- ₹0
- Capital Expenditure
- ₹0
- Dividend Payout Ratio
- 0%
Concord Drugs Ltd ended 2024 with ₹582.31 million in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹582.31 million while shareholder equity stood at ₹317.04 million.
Concord Drugs Ltd ended 2024 with ₹0 in deferred long-term liabilities, ₹216.15 million in other current liabilities, in common stock, ₹0 in retained earnings and ₹0.00 in goodwill. Its cash balance stood at ₹783600.00 and cash and short-term investments were ₹0. The company’s total short-term debt was ₹0 while long-term debt stood at ₹19.11 million.
Concord Drugs Ltd’s total current assets stands at ₹434.56 million while long-term investments were ₹0 and short-term investments were ₹1.61 million. Its net receivables were ₹158.10 million compared to accounts payable of ₹52.72 million and inventory worth ₹200.65 million.
In 2024, Concord Drugs Ltd's operating cash flow was ₹0 while its capital expenditure stood at ₹0.
Comparatively, Concord Drugs Ltd paid ₹0 in dividends in 2024.
Other key metrics
- Current Trading Price
- ₹35.18
- 52-Week High
- ₹41.65
- 52-Week Low
- ₹24.8
- Analyst Target Price
- ₹
Concord Drugs Ltd stock is currently trading at ₹35.18 per share. It touched a 52-week high of ₹41.65 and a 52-week low of ₹41.65. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹32.57 and 200-day moving average was ₹30.48 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 0% of the company’s stock are held by insiders while 0% are held by institutions.